bempedoic acid; ezetimibe - Profile

What are the generic drug sources for bempedoic acid; ezetimibe and what is the scope of freedom to operate?

Bempedoic acid; ezetimibe is the generic ingredient in one branded drug marketed by Esperion Theraps Inc and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bempedoic acid; ezetimibe has eighty-three patent family members in twenty-four countries.

Summary for bempedoic acid; ezetimibe

International Patents:	83
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bempedoic acid; ezetimibe

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for bempedoic acid; ezetimibe

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for BEMPEDOIC ACID; EZETIMIBE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXLIZET	Tablets	bempedoic acid; ezetimibe	180 mg/10 mg	211617	3	2024-02-21

US Patents and Regulatory Information for bempedoic acid; ezetimibe

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes

Expired US Patents for bempedoic acid; ezetimibe

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020

EU/EMA Drug Approvals for bempedoic acid; ezetimibe

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Daiichi Sankyo Europe GmbH	Nustendi	bempedoic acid, ezetimibe	EMEA/H/C/004959Nustendi is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibealone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin	Authorised	no	no	no	2020-03-27

International Patents for bempedoic acid; ezetimibe

Country	Patent Number	Title	Estimated Expiration
Australia	2016233485
Australia	2021218120
Australia	2024202106

Supplementary Protection Certificates for bempedoic acid; ezetimibe

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2404890	C 2020 031	Romania		PRODUCT NAME: ACID BEMPEDOIC, SAU O SARE, HIDRAT, SOLVAT ACCEPTABILE FARMACEUTIC SAU AMESTECUL ACESTORA; NATIONAL AUTHORISATION NUMBER: EU/1/20/1424; DATE OF NATIONAL AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1424; DATE OF FIRST AUTHORISATION IN EEA: 20200327
2404890	2020C/534	Belgium		PRODUCT NAME: ACIDE BEMPEDOIQUE OU UN SEL, HYDRATE, PRODUIT DE SOLVATATION OU MELANGE DE CEUX-CI, PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/20/1424 20200331
2404890	LUC00174	Luxembourg		PRODUCT NAME: BEMPEDOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, SOLVATE, OR MIXTURE THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/20/1424 20200331

Investment Scenario, Market Dynamics, and Financial Trajectory for Bempedoic Acid and Ezetimibe

Last updated: February 3, 2026

Summary

This report analyzes the current investment landscape, market dynamics, and financial outlook for two lipid-lowering drugs: bempedoic acid and ezetimibe. Bempedoic acid, marketed as Nexletol (brand by Esperion Therapeutics), is a newer ATP citrate lyase inhibitor approved in 2020 for hypercholesterolemia. Ezetimibe, branded as Zetia (by Merck), has a longer market history since 2002. Both target LDL cholesterol reduction but differ in mechanism and market penetration.

Key highlights:

• Market size for lipid-lowering agents projected to reach USD 18 billion by 2027.
• Bempedoic acid's share is expected to grow from USD 300 million (2023) to over USD 1.5 billion by 2030.
• Ezetimibe remains dominant, comprising approximately 25-30% of the market.
• Competitive landscape involves statins, PCSK9 inhibitors, and emerging therapies.
• Market entry, patent status, and regulatory pathways influence future growth.

This analysis provides insights for investors, pharma strategists, and market analysts seeking data-driven evaluation.

---

What Is the Current Market for Lipid-Lowering Agents?

Parameter	Detail
Global market size (2022)	USD 13.6 billion
Projected (2027)	USD 18.2 billion (CAGR 6-7%)
Major segments	Statins (primary ~70%), Ezetimibe (~15%), PCSK9 inhibitors (~10%), Others (~5%)
Key drivers	Cardiovascular disease prevalence, unmet needs, patent expirations, newer drug approvals

The overall trend indicates a shift toward precision medicine and combination therapies, encouraging aspirations for drugs like bempedoic acid.

---

What Are the Market Dynamics for Bempedoic Acid?

Market Entry and Approval Timeline

Event	Date	Details
FDA Approval	February 2020	First oral ATP citrate lyase inhibitor approved in the US
EMA Approval	May 2020	Approved in Europe
Key Trials	CLEAR Outcomes (2020-2022)	Demonstrated LDL reductions and safety profile

Market Penetration and Adoption

• Launched as a second-line agent for statin-intolerant patients and in combination therapy.
• Prescriptions tied to cardiovascular risk assessment guidelines.
• Collaborations with pharmacy chains and payers to increase utilization.

Pricing and Reimbursement

Pricing (US)	Approximate	Notes
Per 30-day supply	USD 460	About 20% cheaper than PCSK9 inhibitors
Reimbursement status	Varies	Coverage improves with demonstrated cardiovascular benefit

Competitive Position

Competitors	Market Share (2023)	Strengths	Weaknesses
Ezetimibe	~25-30%	Established, extensive safety data	Less potent LDL reduction
PCSK9 inhibitors (evolocumab, alirocumab)	~15-20%	High efficacy	High cost, injection only
Bempedoic acid	Growing	Oral, suitable for combination	Limited long-term data

Regulatory and Patent Outlook

Patent Expiry	Expected	Impact
Nexletol patents	2030-2035	Allows for market extension and biosimilar development

---

What is the Financial Trajectory for Ezetimibe?

Market Position

• Ezetimibe remains a frontline add-on therapy; combined with statins, it enhances LDL reduction.
• Estimated USD 2.7 billion in global sales (2022), sustaining steady growth.
• Patent expired in 2018 in the US, leading to generic versions and price erosion.

Market Share and Sales Trends

Year	Estimated Sales (USD Billions)	Notes
2022	2.7	Steady sales, decline in branded versions
2025	2.3	Generic competition intensifies
2030	2.0	Continued erosion but maintained niche

Revenue Streams and Cost Dynamics

• Generic dominance has lowered per-unit costs.
• Brand manufacturers focus on formulary inclusion and combination therapies.
• Limited potential for significant growth unless combined with emerging lipid therapies.

---

How Do Future Market Trends Affect Investment?

Emerging Therapies and Market Competition

Potential Disruptors	Impact	Status
Bempedoic acid	Capturing early adopters, especially statin-intolerant	Growth phase
Inclisiran (siRNA)	Long-acting LDL-C lowering	Approved in US/Europe, expanding indications
Gene therapies (e.g., LPL)	Potential for durable lipid management	Clinical trials ongoing

Regulatory Environment and Policy Trends

• Guidelines (e.g., American College of Cardiology) increasingly recommend combination therapies.
• Payer policies favor cost-effectiveness; drugs with proven cardiovascular outcome benefits secure reimbursement.

Pricing Strategies & Patent Landscapes

Strategy	Details
Market penetration through partnerships	Outcomes-based reimbursement, co-promotion
Patent extensions	Data exclusivity, new formulations
Biosimilar entry	Further price reductions

---

Financial Outlook and Investment Viability

Parameter	Projection (2023-2030)	Implications
Bempedoic acid sales	USD 300 million (2023) to USD 1.5-2 billion (2030)	Significant growth with expanding indications
Ezetimibe revenues	Steady decline, stabilizing ~USD 2 billion	Limited growth, focus shifts to combination therapy sales
Market share shifts	Bempedoic acid gaining 10-15%	Emerging as a key oral LDL-lowering drug

---

Comparison Table: Bempedoic Acid vs. Ezetimibe

Feature	Bempedoic Acid	Ezetimibe
Mechanism	ATP Citrate Lyase inhibition	Cholesterol absorption inhibitor
Approval Year	2020	2002
Administration	Oral	Oral
Primary Use	Statin-intolerant, adjunct	Add-on therapy with statins
Market Penetration	Growing	Mature, declining
Patent Status	Valid until 2030-2035	Expired in many regions
Long-term Data	Limited	Extensive (>20 years)

---

Key Takeaways

• Market growth prospects for bempedoic acid are favorable, driven by clinical adoption, especially in statin-intolerant populations.
• Ezetimibe's role remains significant but is declining due to patent expiration and generic competition.
• Competitive landscape shifts toward high-efficacy, durable LDL-lowering agents like PCSK9 inhibitors and novel modalities.
• Pricing and reimbursement strategies are crucial for market expansion, with value-based approaches gaining momentum.
• Emerging therapies could disrupt market share but also offer new partnership and investment opportunities.

---

FAQs

1. What factors influence the adoption of bempedoic acid in clinical practice?
Patient tolerability, guidelines endorsing its use, demonstration of cardiovascular outcome benefits, and payer coverage significantly impact adoption.

2. How does the efficacy of bempedoic acid compare to ezetimibe?
Bempedoic acid reduces LDL-C by approximately 18-23%, whereas ezetimibe offers 15-20% reduction. Combined therapy enhances lipid lowering.

3. What are the long-term safety concerns for bempedoic acid?
Current trials indicate a safety profile similar to placebo, but long-term cardiovascular outcome data are limited; ongoing studies aim to clarify this.

4. How will patent expirations affect ezetimibe’s market share?
Patent expiry in 2018 led to price erosion and generic proliferation, reducing revenues and market dominance.

5. What regulatory trends could impact future drug development in this field?
Accelerated pathways, outcome-based approvals, and increased emphasis on cost-effectiveness influence R&D and commercialization strategies.

---

References

1. Market data and projections: [1] Grand View Research, 2022; [2] MarketsandMarkets, 2022
2. Drug approval and trial data: U.S. Food and Drug Administration (FDA), 2020; European Medicines Agency (EMA), 2020
3. Patent expiration info: FDA Orange Book, 2022
4. Guidelines: ACC/AHA 2018 Guidelines for Lipid Management
5. Competitive landscape analysis: EvaluatePharma, 2022

---

This comprehensive evaluation provides a business-focused understanding of bempedoic acid and ezetimibe, offering strategic insights for informed investment and market positioning.